Adults and children with serious chronic health conditions, including cancer, are at higher risk of developing more serious complications from contagious illnesses such as COVID-19. This page provides some suggestions for people with cancer, including those taking part in clinical trials, as they navigate the coronavirus pandemic.
Results from a large clinical trial are expected to change treatment for people with advanced AIDS-related Kaposi sarcoma in sub-Saharan Africa. In the trial, paclitaxel greatly improved outcomes compared with treatments typically used in the region.
Results from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). Selumetinib shrank the inoperable tumors that develop with NF1, and children experienced reduced pain, improved function, and better overall quality of life.
Kathleen Wall helps people with brain and spine cancers understand and participate in clinical trials designed to find new ways to treat them and improve their quality of life. In this NCI-CONNECTions blog post, she shares information people need to know about clinical trials.
Clinical Trials Information for Patients and Caregivers
Learn how to gather details about your cancer, places to search for clinical trials, how to narrow your search, and questions to ask to help you find a trial that is appropriate for you.
This phase 1 trial is testing a CAR T-cell therapy using chlorotoxin in patients with glioblastoma. Chlorotoxin, a chemical found in scorpion venom, binds to glioblastoma cells that lack other commonly targeted tumor-related antigens. Doctors will assess the safety of the therapy and determine the maximum tolerated dose.
This phase 1 trial will test a mesothelin-targeted immunotoxin, LMB-100, and the targeted drug tofacitinib (Xeljanz) for patients with previously treated pancreatic cancer, bile duct cancer, or other solid tumors that express the protein mesothelin. Doctors will assess the safety and tolerability of the regimen, as well as determine if giving patients tofacitinib delays the formation of proteins that block the effect of LMB-100.
